Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis
A Pilot Study to Investigate the Use of Topical Levulan® With Vbeam® Laser for the Treatment of Actinic Keratoses
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using topical aminolevulinic acid may be effective against actinic keratosis.
PURPOSE: This randomized clinical trial is studying how well different photodynamic therapy regimens using topical aminolevulinic acid work in treating patients with actinic keratosis.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
Primary
- To determine, using fluorescence measurements, the protoporphyrin IX (PpIX) accumulation in thin actinic keratoses (AK) and actinically damaged skin on the face, scalp, and upper torso (stratum 1) and the PpIX accumulation in thick AK and actinically damaged skin on the arms and legs (stratum 2) as a function of skin preparation, aminolevulinic acid (ALA) application time, and body site.
- To determine the extent that the PpIX is photobleached by the treatment light.
Secondary
- To assess the effects of different treatment conditions on acute reactions of AK and sun damaged skin to ALA-photodynamic therapy (PDT) occurring 24-48 hours after PDT.
- To assess the effects of different treatment conditions on the efficacy of ALA-PDT.
- To examine the histological response to ALA-PDT.
- To determine, using fluorescence measurements, the PpIX accumulation in incidental thick AK that may occur in stratum 1, and the PpIX accumulation in incidental thin AK that may occur in stratum 2 as a function of skin preparation, ALA application time and body site.
- To determine the extent that the PpIX in these incidental lesions is photobleached by treatment light.
OUTLINE: The randomization is a two-step restricted block process for application time and skin preparation, followed by randomization for light dose (1 vs 2 pulses) within the anatomic site. Within each stratum (stratum 1 or 2), lesions in each separate anatomic area (face and neck, scalp, upper torso; arms, legs) are randomized to receive 1 of 3 pretreatment skin preparation before receiving topical aminolevulinic acid (ALA): pretreatment with acetone, gentle abrading, or no pretreatment. Patients are randomized to receive ALA at different times before the photodynamic therapy (PDT).
- Arm I: Patients receive topical ALA 2 hours before PDT.
- Arm II: Patients receive topical ALA 4 hours before PDT.
- Arm III: Patients receive topical ALA 24 hours before PDT. Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face). The subunits are randomized to receive 1 or 2 pulses of the laser treatment.
- Arm IV: 1 Vbeam laser pulse (photodynamic therapy) is applied to the subunit.
- Arm V: 2 Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart. Patients with progressive lesions or lesions that have not responded after 3 treatments may receive diagnostic biopsy to check for invasive squamous cell carcinoma and referred to treatment off study.
Patients undergo biopsies at baseline, before and after ALA application prior to light treatment, and up to 24 hours after light treatment to analyze cytokines and genes specific to actinic keratoses.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
New York
-
Buffalo, New York, États-Unis, 14263-0001
- Roswell Park Cancer Institute
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Actinic keratosis lesion located in any of the following body sites:
Stratum 1*: face and neck, scalp, or upper torso
- At least 1 clinically evident thin actinic keratosis on each side of the midline of any of the above areas
Stratum 2*: arms or legs
- At least 1 clinically evident thick actinic keratosis on each arm or leg NOTE: *One patient may be in one or both strata depending on the location of the lesion(s)
- Lesions to be treated on this protocol must not have been previously treated by other modalities for at least 2 months prior to study entry
PATIENT CHARACTERISTICS:
- No porphyria or known hypersensitivity to porphyrins
- No known photosensitivity disease
- No known sensitivity to any components of aminolevulinic acid topical solution
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
- Other concurrent topical therapies at lesion sites other than those used in this protocol are allowed
- No other concurrent photosensitizer drugs
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm 1 - ALA
Patients receive topical ALA topical (aminolevulinic acid) 2 hours before PDT.
|
|
|
Expérimental: Arm 2
Patients receive topical ALA topical (aminolevulinic acid) 4 hours before PDT
|
|
|
Expérimental: Arm 3
Patients receive topical ALA (aminolevulinic acid) 24 hours before PDT.
Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face).
The subunits are randomized to receive 1 or 2 pulses of the laser treatment
|
|
|
Expérimental: Arm 4
Vbeam laser pulse (photodynamic therapy) is applied to the subunit
|
|
|
Expérimental: Arm 5
Vbeam laser pulses (photodynamic therapy) are applied to the subunit.
Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
|---|
|
Protoporphyrin IX (PpIX) Accumulation as a Function of Skin Preparation, Aminolevulinic Acid Application Time, and Body Site
|
|
Extent That the PpIX is Photobleached by the Treatment Light
|
Mesures de résultats secondaires
Mesure des résultats |
|---|
|
Effects of Different Treatment Conditions on Acute Reactions of Actinic Keratoses (AK) and Sun Damaged Skin Occurring 24-48 Hours After Photodynamic Therapy
|
|
Effects of Different Treatment Conditions on Efficacy
|
|
Histological Response
|
|
PpIX Accumulation in Incidental AK as a Function of Skin Preparation, Aminolevulinic Acid Application Time, and Body Site
|
|
Extent That the PpIX is Photobleached by the Treatment Light in Incidental Lesions
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Nathalie Zeitouni, MD,, Roswell Park Cancer Institute
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- I 28204
- RPCI-I-28204
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .